The potential applications of mushrooms against some facets of atherosclerosis: A review

Food Res Int. 2018 Mar:105:517-536. doi: 10.1016/j.foodres.2017.11.023. Epub 2017 Nov 21.

Abstract

Atherosclerosis is a complex pathology that involves several factors in its development, like oxidative stress, inflammation, hyperlipidemia, platelet aggregation and thrombus formation. Several drugs and therapeutic approaches have been developed to handle these aspects of atherosclerosis. However, some of these treatments can be costly and have undesirable side effects. Many constituents of mushrooms have been shown to have potential anti-atherosclerotic effects in several in vitro and in vivo studies. Recently, the possible mechanisms in which they exert these effects have also been elucidated. In this review, some of the research focusing on mushrooms and their potential anti-atherosclerotic effects are examined. Many mushroom species exhibited anti-oxidative, anti-inflammatory and hypolipidemic effects that can potentially attenuate the progression of atherosclerosis, either through their isolated compounds or use of crude extracts. More studies are focused on the effect that mushrooms have on gene expressions that are involved in oxidative stress, inflammation, and hyperlipidemia. These studies could provide us with a better understanding on the mechanisms in which the consumption of mushrooms could exert their possible anti-atherosclerotic effects. Further research needs to be done to uncover other possible mechanisms that are affected by mushroom use.

Keywords: Cardiovascular diseases; Fungi; Hyperlipidemia; Inflammation; Oxidative stress; Thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Agaricales / chemistry*
  • Animals
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / isolation & purification
  • Anti-Inflammatory Agents / therapeutic use*
  • Antioxidants / adverse effects
  • Antioxidants / isolation & purification
  • Antioxidants / therapeutic use*
  • Arteries / drug effects*
  • Arteries / metabolism
  • Arteries / pathology
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / pathology
  • Biomarkers / blood
  • Blood Coagulation / drug effects
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / isolation & purification
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / isolation & purification
  • Hypolipidemic Agents / therapeutic use*
  • Inflammation Mediators / blood
  • Lipids / blood
  • Oxidative Stress / drug effects
  • Plaque, Atherosclerotic
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / isolation & purification
  • Platelet Aggregation Inhibitors / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Biomarkers
  • Fibrinolytic Agents
  • Hypolipidemic Agents
  • Inflammation Mediators
  • Lipids
  • Platelet Aggregation Inhibitors